NCT05006677招募中不适用
Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus
China National Center for Cardiovascular Diseases1 个研究点 分布在 1 个国家目标入组 480 人开始时间: 2021年8月4日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 480
- 试验地点
- 1
- 主要终点
- Thrombus resolution in 12 weeks follow-up
研究概览
简要总结
To observe the effectiveness and safety of different therapies-non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) or antiplatelet agents and non-antithrombotic therapy - for the treatment of VT.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults with ventricular thrombus(VT), regardless of sex, basic diseases, occupation or education;
- •The VT should be found newly within 3 months;
- •The observational phase should last until the time that patients who had achieved thrombus resolution. The following up period after the phase ended should continue for at least 3 months.
排除标准
- •Individuals received standard antithrombotic therapy within 4 weeks;
- •Individuals received the thrombectomy therapy, ventricular aneurysm resection or heart transplantation within 6 weeks since the VT was found in the first time;
- •Had a long history of VT more than three months.
研究组 & 干预措施
non-vitamin K antagonist oral anticoagulants (NOACs)
干预措施: non-vitamin K antagonist oral anticoagulants (NOACs) (Drug)
vitamin K antagonists (VKAs)
干预措施: vitamin K antagonists (VKAs) (Drug)
antiplatelet agents
干预措施: antiplatelet agents (Drug)
non-antithrombotic therapy
干预措施: non-antithrombotic therapy (Other)
结局指标
主要结局
Thrombus resolution in 12 weeks follow-up
时间窗: 12 weeks
Thrombus resolution in 12 weeks follow-up
次要结局
- Thrombus resolution in 6 weeks follow-up(6 weeks)
- Thromboembolism events(12 months)
- All-cause death(12 months)
- Thrombus resolution in 12 months follow-up(12 months)
- Bleeding(12 months)
- Thrombus resolution in 6 months follow-up(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
NOACs Use in AF or VTE (SUNSHINE Registry)Oral AnticoagulantAtrial FibrillationVenous ThromboembolismNCT05378308Henan Provincial People's Hospital5,000
已完成
不适用
Comparison of Accidents and Their Circumstances With Oral AnticoagulantsCardiovascular ComplicationsHemorrhagic DisordersEmbolism and ThrombosisNCT02376777CNGE IRMG Association4,162
已完成
4 期
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)Atrial Fibrillation Patients With Intermediate Stroke RiskNCT04437654Yonsei University1,803
已完成
2 期
NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICHIntracerebral HemorrhageAtrial FibrillationNCT02998905Population Health Research Institute30
招募中
不适用
Evaluataion of NOAC Levels in Acute StrokeIschemic StrokeAnticoagulant Adverse ReactionNCT06144866National Taiwan University Hospital1,000
